Skip to main navigation

Sagimet Biosciences

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

News Releases

Year

3/27/2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

3/25/2024

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

3/25/2024

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

2/29/2024

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

1/25/2024

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

1/23/2024

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

1/22/2024

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Site Map

About
Science
Investors
Programs
Contact

Contact Us

Business Development:
bd@sagimet.com

Investors:
ir@sagimet.com

Media:
media@sagimet.com

© 2024 Sagimet Biosciences Inc. All Rights Reserved.

Close line1 Close line2

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact